Exploring biomarkers in blood and urine for breast cancer diagnosis
Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06102018
This study is trying to find new blood and urine markers that can help tell if someone has early breast cancer, comparing samples from patients with cancer, those with non-cancerous issues, and healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (other) |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06102018 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify diagnostic biomarkers in serum and urine from patients with early breast cancer. It will compare various biomarkers from breast cancer patients, those with benign lesions, and healthy individuals. The study will also utilize machine learning to develop a diagnostic model that effectively distinguishes between breast cancer and non-breast cancer patients. Participants will provide blood and urine samples during their diagnosis and treatment, ensuring that their original treatment remains unchanged.
Who should consider this trial
Good fit: Ideal candidates include female patients with a breast mass who require surgery and have signed informed consent.
Not a fit: Patients with other malignant tumors or those whose internal organs are deemed unsuitable for participation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and non-invasive diagnostic methods for early breast cancer detection.
How similar studies have performed: While similar studies exploring biomarkers have shown promise, this specific approach utilizing machine learning for diagnostic modeling is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signing the consent of informedness; 2. Patients with breast mass who need surgery after examination; 3. Cardiac ultrasound indicates that the blood score of the heart is within the normal range; 4. ECOG≤0-2 points; 5. Oversure function is acceptable. Exclusion Criteria: 1. Merge other malignant tumors such as gynecologic oncology; 2. After evaluation, the internal organs are not suitable.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Study coordinator: Jieqiong Liu Ph.D.
- Email: liujieqiong01@163.com
- Phone: 13922272706
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Neoplasm Female, Serum and Urine Biomarkers,Machine Learning,Diagnostic Model